RAF, MEK and ERK Inhibitors as Anti-Cancer Drugs: Intrinsic and Acquired Resistance as a Major Therapeutic Challenge
Crossref DOI link: https://doi.org/10.1007/978-3-319-67932-7_5
Published Online: 2018-03-29
Published Print: 2018
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Maik-Rachline, Galia
Cohen, Izel
Seger, Rony
License valid from 2018-01-01